03:57 AM EDT, 09/20/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said late Thursday the US Food and Drug Administration has approved Rybrevant in combination with chemotherapy for the treatment of adult patients with certain forms of locally advanced or metastatic non-small cell lung cancer.

The FDA approval is based on results from a phase 3 study that showed Rybrevant plus chemotherapy reduced the risk of disease progression or death by 52% compared with chemotherapy alone, meeting its primary endpoint, the company said.

Price: 165.00, Change: +0.18, Percent Change: +0.11